1343 results about "Pyrazine" patented technology

Provided herein are polymorphs and crystalline forms of 2-fluoro-5-((5S,5aS,6S,9R)-1-fluoro-12-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-5-methyl-5a,6,7,8,9,10-hexahydro-5H-4-oxa-3,10a,11,13,14-pentaaza-6,9-methanonaphtho[1,8-ab]heptalen-2-yl)-3-methyl-4-(trifluoromethyl)aniline (Compound of Formula (I)), pharmaceutical compositions thereof, and methods of their use, for example, in the treatment of cancer. Also provided herein are synthetic processes for the manufacture of a compound of Formula (I) (i.e., 2-fluoro-5-((5S,5aS,6S,9R)-1-fluoro-12-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-5-methyl-5a,6,7,8,9,10-hexahydro-5H-4-oxa-3,10a,11,13,14-pentaaza-6,9-methanonaphtho[1,8-ab]heptalen-2-yl)-3-methyl-4-(trifluoromethyl)aniline). Also provided are compounds useful in its synthesis (e.g., those of Formulae (A), (B), (By), and (H)) and synthetic processes directed thereto.

An advantageous isolated morphic form of trilaciclib which is 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.

The invention belongs to the technical field of white spirit brewing, and particularly relates to bacillus velezensis BL-LM and application thereof in preparation of special-flavor white spirit yeast. The bacterial strain is classified and named as Bacillus velezensis, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.30130. The invention further discloses a preparation method of the bacterial strain. When the bacillus velezensis BL-LM is added into starter propagation raw materials, in the starter propagation process, the top fire temperature of a starter blank is high, the temperature rising time is long, the liquefying power and saccharifying power activity of the starter blank is higher, the capacity of producing white spirit characteristic flavor substances such as pyrazines, guaiacol and 4-vinyl guaiacol is higher, and the content of organic acid is high. The bacillus velezensis BL-LM disclosed by the invention has a relatively good promotion effect on physicochemical property optimization and flavor substance generation of the specially-fragrant yeast, and has a very obvious effect in the aspect of modifying the quality of the specially-fragrant yeast.

The invention relates to a conjugated microporous polymer based on a dicarbazole structure and a preparation method and application thereof, the conjugated microporous polymer has a dicarbazole structure unit and a nitrogen-containing aromatic structure unit, the dicarbazole monomer structure is represented by the formula (I): # imgabs0 #, in the structure represented by the formula (I): R = H, R1 = C = H or R1 = H, R = C = H; the structure of the nitrogen-containing aromatic monomer is shown as a formula (II): # imgabs 1 #, wherein the aromatic structure in the structure shown as the formula (II) is any one of benzene, pyridine, pyrimidine, pyrazine and pyridazine. A plurality of conjugated microporous polymers with excellent photocatalytic performance are obtained by changing aromatic monomers with different nitrogen contents, and the conjugated microporous polymers can be applied to high-efficiency production of hydrogen peroxide under photocatalytic conditions.

The invention belongs to the technical field of crystalline materials, particularly relates to a calcium-based metal organic framework material, a preparation method thereof and application of the calcium-based metal organic framework material in carbon dioxide trapping, and provides a calcium-based metal organic framework material formed by using 2, 5-pyrazine dicarboxylic acid as a ligand and calcium salt through a solvothermal method. The calcium-based metal organic framework material can generate transformation of unit cell parameters when removing guest molecules and adsorbing CO2 molecules, the metal-organic framework material is constructed by taking acetonitrile as a template agent, and due to the similarity of acetonitrile and CO2 molecules, the MOF has potential application in the aspect of CO2 trapping.

The invention discloses a method for increasing the content of pyrazines and 2, 3-butanediol substances through high-temperature Daqu micro-ecological regulation and control, and belongs to the technical field of microbial food processing. The invention discloses a method for improving the content of pyrazines and 2, 3-butanediol substances through micro-ecological regulation and control of high-temperature yeast for making hard liquor, and the method comprises the following steps of: combining and inoculating strains, namely bacillus subtilis CGMCC (China General Microbiological Culture Collection Center) 10830, bacillus velezensis CGMCC 7044 and bacillus licheniformis CGMCC 20675, into wheat flour according to a proportion to prepare the high-temperature yeast for making hard liquor. According to the invention, not only are the contents of pyrazine substances and 2, 3-butanediol increased, but also the abundance of beneficial microorganisms such as bacillus, thermophilic fungi and the like is remarkably improved, and a good saccharification fermentation agent is provided for brewing high-quality white spirit.

An advantageous isolated morphic form of trilaciclib which is 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, for example in the form of a dihydrochloride salt or a dihydrochloride, dihydrate.

The present invention relates to compounds of formula I. The compounds of the present invention are SMARCA4 protein degradation agents for the treatment of cancer. # imgabs0 #

An advantageous isolated morphic form of trilaciclib which is 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, for example in the form of a dihydrochloride salt or a dihydrochloride, dihydrate.

An advantageous isolated morphic form of trilaciclib which is 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, for example in the form of a dihydrochloride salt or a dihydrochloride, dihydrate.

The invention discloses an aggregation-induced emission metal organic framework, a preparation method thereof and application of the aggregation-induced emission metal organic framework in portable detection of low-concentration nitrobenzene. According to the aggregation-induced emission metal organic framework, ZrCl4 provides Zr < 4 + >, 2-sulfonic terephthalic acid and AIE molecule 2, 3, 5, 6-tetra (4-carboxyl phenyl) pyrazine as organic ligands, an aggregation-induced emission fluorescent material is obtained through a solvothermal method, due to the coordination effect and limited intramolecular rotation, the material shows bright blue fluorescence, and the fluorescence intensity of the aggregation-induced emission metal organic framework is greatly improved. The aggregation-state fluorescence can be obviously quenched after the fluorescent probe is contacted with nitrobenzene. The aggregation-induced emission metal organic framework material is obtained by utilizing the aggregation-induced emission performance of aggregation-induced emission molecules, and the material has good detection capability on nitrobenzene, can rapidly and efficiently detect nitrobenzene in a solution, and has good cycle performance. Meanwhile, the nitrobenzene gas can be detected for multiple times, and good sensitivity and practicability are achieved.

The invention discloses a preparation method of silver-coated copper powder. The preparation method comprises the following steps: reacting copper-containing complexing mother liquor, a silver source and a reducing agent; the copper-containing complexing mother liquor is prepared from the following raw materials: copper powder, a chelating agent, a dispersing agent and a modification additive; the modification additive comprises at least one of ethylenediamine, ammonium carbonate, ammonia water, tetraethylenepentamine, polyethylene polyamine, imidazole, pyridazine, pyrimidine and pyrazine. According to the preparation method of the silver-coated copper powder, the silver coating layer of the prepared silver-coated copper powder is uniform and compact, and controllable preparation of the silver-coated copper powder with different appearances is achieved.

The invention discloses a structure-reversible intervariant metal frame adsorption material and a preparation method and application thereof, and belongs to the technical field of adsorption materials, and the preparation method comprises the following steps: dissolving anhydrous calcium chloride and 2, 5-pyrazine dicarboxylic acid in a mixed solvent, then adding concentrated nitric acid, carrying out a heating reaction, continuing to activate the obtained solid product at 50-420 DEG C for 24 h, filtering, washing, and drying to obtain the structure-reversible intervariant metal frame adsorption material. And realizing structural transformation to obtain the intervariant metal frame adsorption material with the reversible structure. The reversible intervariant metal framework provided by the invention provides a new strategy for research and development of multifunctional MOFs materials, so that the material can adjust the pore characteristics and the three-dimensional space structure according to the temperature change, and the macroscopic adsorption performance is obviously influenced. The preparation process provided by the invention is simple and convenient, and a new strategy is provided for cadmium ion sewage treatment.

Disclosed is a pharmaceutical composition for the treatment of tumors, the pharmaceutical composition comprising (6S, 9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl) azetidin-1-yl] pyridin-2-yl} methyl)-6-(2-fluoro-4-hydroxybenzyl)-4, 7-dioxo-2-(propyl-2-en-1-yl) hexahydro-2H-pyrazino [2, 1-c] [1, 2, 3] triazolo [1, 2, 4] triazolo [1, 2, 4] triazolo [1, 2, 4] triazolo [1, 2, 4] triazolo [1, 2, 4] triazolo [1, 2, 4] triazolo [1, 2, 4] triazolo [1, 2, 4] triazolo [ The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof and administered in combination with a MEK inhibitor.

The invention belongs to the technical field of organic framework materials, and particularly relates to a pyrazinyl monomer and a preparation method and application of a covalent organic framework material of the pyrazinyl monomer. Three nitrogen-rich methyl monomers containing pyrazine groups are designed and synthesized, the monomers and aromatic dialdehyde can be subjected to a condensation reaction to form a series of vinyl covalent organic frameworks (COFs), and the prepared three nitrogen-rich vinyl COFs can be applied to the field of gas adsorption and separation.

A pyrazine thio-biphenyl compound and its application, specifically discloses the compound of formula (II) or a pharmaceutically acceptable salt thereof.

The invention belongs to the technical field of lithium organic batteries, and provides a conjugate extended lithium-containing organic positive electrode material and a preparation method and application thereof. The synthesis process of the positive electrode material comprises the following steps: firstly, taking tetraamino p-benzoquinone as a raw material, and carrying out oximation modification reaction on the tetraamino p-benzoquinone to generate tetraamino p-oximic acid; then, carrying out composite treatment on the TAPO and a lithium source to obtain lithium tetraamino p-oximate; and finally, through a condensation polymerization reaction, further preparing to obtain the polybenzoquinone-pyrazine extended lithium oximate. Through specific chemical treatment, the organic material contains a lithium element, so that the dependence on an external lithium source (such as a metal lithium negative electrode or a lithium supplement agent) is eliminated. Through ingenious molecular design and synthesis strategies, the conductivity of the material is improved, and the rate capability, the solubility resistance, the high-temperature stability and the cycle life of the material are remarkably enhanced, so that a solid foundation is laid for long-term stable operation and high-performance expression of a battery.

A pharmaceutical composition comprising sitagliptin or a pharmaceutically acceptable salt thereof, wherein the composition comprises less than 5 ppm of 7-Nitroso-3-(trifluoromethyl)- 5,6,7,8-tetrahydr

The disclosure provides a solid form of 5-fluoro-1-(((5S,7S,8R)-8- fluoro-3-(5-(2-hydroxypropan-2-yl)pyrazin-2-yl)-7-methyl-2-oxo-1- oxa-3-azaspiro[4.5]decan-7-yl)methyl)-1H-benzo[d]imidazole-6- carbonitrile: The compound is useful as TRPV4 antagonists.

The invention relates to a pyrazinyl covalent organic framework material as well as a preparation method and application thereof, 2, 5-dimethylpyrazine and aromatic aldehyde monomers are taken as construction elements, and the pyrazinyl covalent organic framework material connected with two olefins is synthesized through a Knoevenagel reaction. The pyrazinyl covalent organic framework material disclosed by the invention has good chemical stability and full-conjugate skeleton characteristics, shows excellent photocatalytic activity and cycling stability in visible light driven thioether oxidation reaction, and has potential application value in the fields of environmental restoration and green chemistry.

The invention relates to the technical field of organic chemistry, in particular to application of pyrazine compounds in the aspect of killing nematodes. The pyrazine compound has good nematicidal activity on pine wood nematodes, root-knot nematodes and aphelenchoides besseyi, and part of the pyrazine compound also has good activity on root knot nematode diseases caused by the root-knot nematodes, so that the pyrazine compound has good application prospects in the aspect of root knot nematode disease resistance.

The present disclosure provides a catalyst system capable of selectively hydrogenating (2, 3) / (4, 5) and (2, 3) / (5, 6) dienones with hydrogen. In particular, the present disclosure provides catalysts capable of providing high selectivity for reduction even in the absence of catalyst poisons such as pyridine, pyrazine, quinoline, and quinoxaline.

The invention discloses a pyrazinamide compound, which is a compound with a structure as shown in a general formula (I) or a tautomer, an enantiomer, a diastereomer, a racemate, a metabolite or a metabolic precursor of the compound, or pharmaceutically acceptable salt, ester and prodrug of the compound, or a hydrate of the compound, the invention also discloses a preparation method of the pyrazinamide compound and an application of the pyrazinamide compound in preparation of medicines for preventing and treating GPR52 related diseases. The invention also discloses a preparation method of the pyrazinamide compound and an application of the pyrazinamide compound in preparation of medicines for preventing and treating GPR52 related diseases.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

Provided are crystalline forms of N-methyl-N-((1s,3s)-3-methyl-3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide, pharmaceutical compositions, methods of use and methods of making thereof.

The present invention relates to a pyrazine derivative, an application thereof in inhibiting SHP2, and a compound of formula (I) or pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope labels thereof. The structure of the compound of formula (I) is as follows. The novel pyrazine derivative provided by the present invention has excellent inhibition of SHP2 activity and can be used to prevent and / or treat non-receptor protein tyrosine phosphatase-mediated or dependent diseases or disorders.

The application belongs to the technical field of etching liquid, and particularly relates to an anti-crystallization copper etching liquid and a preparation method and application thereof. The copper etching liquid is obtained by mixing hydrogen peroxide, inorganic acid, organic acid, fluorine compound, hydrogen peroxide stabilizer, organic sulfonic acid sodium salt, pyrazine polycarboxylic acid, amino acid ionic liquid and water. The components in the copper etching liquid jointly act, so that the phase stability of the copper etching liquid is significantly improved, the copper etching liquid can avoid crystallization in long-time work, and is suitable for industrial application.

The present disclosure relates to solid-state forms and corresponding pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, and methods of treatment, including treatment of rheumatoid arthritis and juvenile idiopathic arthritis using the same. The treatment methods generally comprise administering to a patient (e.g., a pediatric patient) a therapeutically effective amount of upadacitinib as a stable liquid pharmaceutical composition or a solid dosage form, at a dose based on patient body weight.